Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

In vitro microbiological characterization of novel cyclic homopentapeptides, CP-101,680 and CP-163,234, for animal health use.

Norcia LJ, Silvia AM, Dirlam JP, Schnur RC, Bergeron JM, Retsema JA, Hayashi SF.

J Antibiot (Tokyo). 1999 Nov;52(11):1007-16.

2.

Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity.

An WG, Schnur RC, Neckers L, Blagosklonny MV.

Cancer Chemother Pharmacol. 1997;40(1):60-4.

PMID:
9137531
3.

erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships.

Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, DiOrio CI, Barbacci EG, Miller PE, et al.

J Med Chem. 1995 Sep 15;38(19):3813-20.

PMID:
7562912
4.

Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.

Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, et al.

J Med Chem. 1995 Sep 15;38(19):3806-12.

PMID:
7562911
5.

Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185.

Miller P, Schnur RC, Barbacci E, Moyer MP, Moyer JD.

Biochem Biophys Res Commun. 1994 Jun 30;201(3):1313-9.

PMID:
7912926
6.

Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.

Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD.

Cancer Res. 1994 May 15;54(10):2724-30.

7.

Quantitative structure-activity relationships of antitumor guanidinothiazolecarboxamides with survival enhancement for therapy in the 3LL Lewis lung carcinoma model.

Schnur RC, Gallaschun RJ, Singleton DH, Grissom M, Sloan DE, Goodwin P, McNiff PA, Fliri AF, Mangano FM, Olson TH, et al.

J Med Chem. 1991 Jul;34(7):1975-82.

PMID:
2066970
9.

Rotationally restricted mimics of rigid molecules: nonspirocyclic hydantoin aldose reductase inhibitors.

Rizzi JP, Schnur RC, Hutson NJ, Kraus KG, Kelbaugh PR.

J Med Chem. 1989 Jun;32(6):1208-13.

PMID:
2498517
10.

Spiro hydantoin aldose reductase inhibitors.

Sarges R, Schnur RC, Belletire JL, Peterson MJ.

J Med Chem. 1988 Jan;31(1):230-43.

PMID:
3121857
11.

Improved glucose tolerance in rats treated with oxazolidinediones.

Schnur RC, Morville M.

J Med Chem. 1986 May;29(5):770-8.

PMID:
3701788
12.

Spiro oxazolidinedione aldose reductase inhibitors.

Schnur RC, Sarges R, Peterson MJ.

J Med Chem. 1982 Dec;25(12):1451-4.

PMID:
6818344

Supplemental Content

Loading ...
Support Center